Literature DB >> 20835819

Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry.

Patricia M W Lam1, Timothy H Marczylo, Justin C Konje.   

Abstract

Endocannabinoids including N-acylethanolamides (NAEs) are a family of lipid-related signaling molecules implicated in many physiological and disease states which elicit their activities via the cannabinoid receptors. Anandamide (N-arachidonoylethanolamine, AEA) is the most characterized endocannabinoid and has been detected in many tissues and bio-fluids including human plasma and the central nervous system. The endocannabinoid-like NAEs, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are described as entourage compounds because they illicit similar physiological effects to AEA but have little or no affinity for cannabinoid receptors. As entourage compounds, levels of these NAEs can greatly influence the efficacy of AEA yet there are few studies which measure these compounds in bio-fluids. Here we describe a rapid, highly sensitive, specific and highly reproducible ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the analysis of AEA, OEA, and PEA in human bio-fluids including plasma, serum, breast milk, and amniotic fluids. This validated method using deuterated (AEA-d(8), OEA-d(2), and PEA-d(4)) internal standards, represents an improvement over previous analyses in terms of run time (4 min), limit of detection (0.9 fmol on column for AEA and PEA and 4.4 fmol on column for OEA), precision (relative standard deviations of peak areas: 3.1% (AEA), 2.9% (OEA), and 5.4% (PEA) for 133 fmol on column) and accuracy (95.1-104.9%). The sensitivity and precision of the validated method described here suggests that this method is suitable for the analysis of AEA, OEA, and PEA in clinical samples and may be utilized for the investigation of bio-matrices containing limited amounts of NAEs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20835819     DOI: 10.1007/s00216-010-4103-z

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  17 in total

1.  Quantification of 24 circulating endocannabinoids, endocannabinoid-related compounds, and their phospholipid precursors in human plasma by UHPLC-MS/MS.

Authors:  Waldemar Röhrig; Susanne Achenbach; Birgit Deutsch; Monika Pischetsrieder
Journal:  J Lipid Res       Date:  2019-06-24       Impact factor: 5.922

2.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

Review 3.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

4.  Anandamide produced by Ca(2+)-insensitive enzymes induces excitation in primary sensory neurons.

Authors:  Angelika Varga; Agnes Jenes; Timothy H Marczylo; Joao Sousa-Valente; Jie Chen; Jonothan Austin; Srikumaran Selvarajah; Fabiana Piscitelli; Anna P Andreou; Anthony H Taylor; Fiona Kyle; Mohammed Yaqoob; Sue Brain; John P M White; Laszlo Csernoch; Vincenzo Di Marzo; Laki Buluwela; Istvan Nagy
Journal:  Pflugers Arch       Date:  2013-10-10       Impact factor: 3.657

Review 5.  Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

Authors:  C J Hillard; K M Weinlander; K L Stuhr
Journal:  Neuroscience       Date:  2011-11-17       Impact factor: 3.590

Review 6.  The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.

Authors:  Stefania Petrosino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

7.  Endocannabinoids as potential biomarkers: It's all about pre-analytics.

Authors:  Daniel Kratz; Dominique Thomas; Robert Gurke
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-11-10

Review 8.  Endocannabinoids in immune regulation and immunopathologies.

Authors:  Oindrila Rahaman; Dipyaman Ganguly
Journal:  Immunology       Date:  2021-07-08       Impact factor: 7.215

9.  Endocannabinoids measurement in human saliva as potential biomarker of obesity.

Authors:  Isabelle Matias; Blandine Gatta-Cherifi; Antoine Tabarin; Samantha Clark; Thierry Leste-Lasserre; Giovanni Marsicano; Pier Vincenzo Piazza; Daniela Cota
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

Review 10.  Parameters of the Endocannabinoid System as Novel Biomarkers in Sepsis and Septic Shock.

Authors:  J Daniel Lafreniere; Christian Lehmann
Journal:  Metabolites       Date:  2017-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.